Standard BioTools EBITDA Margin 2010-2024 | LAB
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Standard BioTools (LAB) over the last 10 years. The current EBITDA margin for Standard BioTools as of June 30, 2024 is .
Standard BioTools EBITDA Margin Historical Data |
Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
2024-06-30 |
$0.14B |
$-0.14B |
-102.94% |
2024-03-31 |
$0.13B |
$-0.11B |
-82.68% |
2023-12-31 |
$0.11B |
$-0.06B |
-56.60% |
2023-09-30 |
$0.11B |
$-0.06B |
-57.14% |
2023-06-30 |
$0.11B |
$-0.07B |
-65.09% |
2023-03-31 |
$0.10B |
$-0.09B |
-92.78% |
2022-12-31 |
$0.10B |
$-0.10B |
-101.01% |
2022-09-30 |
$0.11B |
$-0.09B |
-81.82% |
2022-06-30 |
$0.11B |
$-0.08B |
-71.68% |
2022-03-31 |
$0.13B |
$-0.06B |
-47.20% |
2021-12-31 |
$0.13B |
$-0.05B |
-38.93% |
2021-09-30 |
$0.14B |
$-0.06B |
-41.30% |
2021-06-30 |
$0.15B |
$-0.04B |
-28.19% |
2021-03-31 |
$0.14B |
$-0.04B |
-26.39% |
2020-12-31 |
$0.14B |
$-0.03B |
-23.74% |
2020-09-30 |
$0.13B |
$-0.03B |
-19.84% |
2020-06-30 |
$0.11B |
$-0.03B |
-30.36% |
2020-03-31 |
$0.11B |
$-0.04B |
-31.58% |
2019-12-31 |
$0.12B |
$-0.03B |
-29.31% |
2019-09-30 |
$0.12B |
$-0.03B |
-28.45% |
2019-06-30 |
$0.12B |
$-0.03B |
-23.53% |
2019-03-31 |
$0.12B |
$-0.02B |
-19.66% |
2018-12-31 |
$0.11B |
$-0.02B |
-19.64% |
2018-09-30 |
$0.11B |
$-0.02B |
-20.37% |
2018-06-30 |
$0.10B |
$-0.03B |
-26.92% |
2018-03-31 |
$0.10B |
$-0.03B |
-33.33% |
2017-12-31 |
$0.10B |
$-0.04B |
-38.83% |
2017-09-30 |
$0.10B |
$-0.05B |
-49.00% |
2017-06-30 |
$0.10B |
$-0.05B |
-53.61% |
2017-03-31 |
$0.10B |
$-0.05B |
-53.47% |
2016-12-31 |
$0.10B |
$-0.06B |
-53.85% |
2016-09-30 |
$0.11B |
$-0.05B |
-48.18% |
2016-06-30 |
$0.12B |
$-0.04B |
-36.75% |
2016-03-31 |
$0.12B |
$-0.04B |
-33.05% |
2015-12-31 |
$0.12B |
$-0.03B |
-29.31% |
2015-09-30 |
$0.12B |
$-0.03B |
-25.42% |
2015-06-30 |
$0.12B |
$-0.04B |
-29.41% |
2015-03-31 |
$0.12B |
$-0.03B |
-28.81% |
2014-12-31 |
$0.12B |
$-0.04B |
-32.48% |
2014-09-30 |
$0.11B |
$-0.04B |
-34.29% |
2014-06-30 |
$0.09B |
$-0.03B |
-33.33% |
2014-03-31 |
$0.08B |
$-0.03B |
-30.49% |
2013-12-31 |
$0.07B |
$-0.02B |
-21.13% |
2013-09-30 |
$0.07B |
$-0.01B |
-21.21% |
2013-06-30 |
$0.06B |
$-0.01B |
-21.31% |
2013-03-31 |
$0.06B |
$-0.01B |
-24.56% |
2012-12-31 |
$0.05B |
$-0.02B |
-30.19% |
2012-09-30 |
$0.05B |
$-0.02B |
-30.00% |
2012-06-30 |
$0.05B |
$-0.02B |
-33.33% |
2012-03-31 |
$0.05B |
$-0.02B |
-39.13% |
2011-12-31 |
$0.04B |
$-0.02B |
-38.64% |
2011-09-30 |
$0.04B |
$-0.02B |
-41.46% |
2011-06-30 |
$0.04B |
$-0.02B |
-42.11% |
2011-03-31 |
$0.04B |
$-0.01B |
-40.00% |
2010-12-31 |
$0.03B |
$-0.01B |
-42.42% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical Information Systems |
$0.830B |
$0.106B |
Standard BioTools Inc. is a solution provider in health and disease using its proprietary mass cytometry and microfluidics technologies. It serves academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories. Standard BioTools Inc., formerly known as Fluidigm Corporation, is based in SOUTH SAN FRANCISCO, Calif.
|